Translating Research Into Practice

Carpenter, William R.; Meyer, Anne Marie; Wu, Yang; Qaqish, Bahjat F.; Sanoff, Hanna K.; Goldberg, Richard M.; Weiner, Bryan J.

doi:10.1097/mlr.0b013e31824ebe13

Cited by 27 publications

(14 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study supports recent findings that institutional and regional characteristics predict hospital use of innovations in cancer care. 11,34 The number of lung cancer cases in the county did not predict whether hospitals ordered the assay or the rate of testing.…”

Section: Discussionmentioning

confidence: 92%

Utilization of epidermal growth factor receptor (EGFR) testing in the United States: a case study of T3 translational research

Lynch

Khoury

Borzecki³

et al. 2013

Genetics in Medicine

View full text Add to dashboard Cite

Purpose We examined hospital use of the epidermal growth factor receptor (EGFR) assay for lung cancer patients. Our goal was to inform the development of a model to predict T3 translation of guideline-directed, molecular diagnostic tests. Methods This was a retrospective observational study. Using logistic regression, we analyzed the association between likelihood to order the EGFR assay and hospital’s institutional and regional characteristics. Results Significant institutional predictors included: Affiliation with an academic medical center (odds ratio [OR], 1.48; 95% CI, 1.20–1.83), Participation in an NCI clinical research cooperative group (OR, 2.06, 1.66–2.55), PET scan (OR, 1.44, 1.07–1.94) and cardio thoracic surgery (OR, 1.90, 1.52–2.37) services. Significant regional predictors included: Metropolitan county (OR, 2.08, 1.48 to 2.91), Above average education (OR, 1.46, 1.09 to 1.96), Above average income (OR, 1.46, 1.04–2.05). Distance from an NCI cancer center was a negative predictor (OR, 0.996, 0.995–0.998), a 34% decrease in likelihood for every 100 miles. Conclusion In 2010, 12% of US acute care hospitals ordered the EGFR assay, suggesting most lung cancer patients did not have access to this test. This case study illustrated the need for: 1) Increased dissemination and implementation research. 2) Interventions to improve adoption of guideline-directed, molecular diagnostic tests by community hospitals.

show abstract

Section: Discussionmentioning

confidence: 92%

Utilization of epidermal growth factor receptor (EGFR) testing in the United States: a case study of T3 translational research

Lynch

Khoury

Borzecki³

et al. 2013

Genetics in Medicine

View full text Add to dashboard Cite

show abstract

“…Moreover, there is growing evidence of their effectiveness in facilitating the diffusion of trial-proven interventions to broader populations. For example, in the context of colorectal cancer, PBRNs have been associated with patients having a greater probability of receiving innovative cancer care [7, 8]. We previously reported on a novel statewide system for ongoing monitoring and public reporting of NCI clinical trial enrollment, developed to extend clinical trials access to broader patient populations [3].…”

Section: Introductionmentioning

confidence: 99%

Enrollment and Racial Disparities in Cancer Treatment Clinical Trials in North Carolina

Zullig¹,

Fortune-Britt

Rao³

et al. 2016

North Carolina Medical Journal

View full text Add to dashboard Cite

Background Clinical trials provide access to innovative, quality cancer treatment. Simultaneously, broad access helps ensure trial inclusion of heterogeneous patient populations, which improves generalizability of findings and development of interventions that are effective for diverse populations. We provide updated data describing enrollment into cancer treatment trials in North Carolina. Methods For 1996 to 2009, person-level data regarding cancer clinical trial enrollment and cancer incidence were obtained from the North Carolina Central Cancer Registry and the National Cancer Institute (NCI). Enrollment rates were estimated as the ratio of trial enrollment to cancer incidence for race, gender, and year for each county, Area Health Education Center (AHEC) region, and the state overall. Enrollment rates for common cancers are presented. Results From 1996 to 2009, North Carolina NCI treatment trial enrollment rate was 2.4% and 2.2% for whites and minorities, respectively. From 2007 to 2009, rates were 3.8% for white females, 3.5% for minority females, 1.3% for white men, and 1.0% for minority men, with greater enrollment among more urban populations (2.4%) than the most rural populations (1.5%). Limitations This study is limited to NCI-sponsored treatment trials in North Carolina. Policies governing collection of original data necessitate a delay in data availability. Conclusions Effort is needed to ensure trial access and enrollment among all North Carolina populations. Specifically, we identified racial and gender disparities, particularly for certain cancers (e.g., breast). Programs in North Carolina and across the nation can use the methods we employ to assess their success in broadening clinical trials enrollment for diverse populations.

show abstract

“…Previously, we have published on an association between CCOP affiliation and innovative chemotherapeutic treatment in colon cancer. [22] Together, these studies suggest that the CCOP PBRN is associated with innovative cancer care in community settings.…”

Section: Discussionmentioning

confidence: 96%

Differential Receipt of Sentinel Lymph Node Biopsy Within Practice-based Research Networks

et al. 2013

Self Cite

View full text Add to dashboard Cite

Background Provider-based research networks (PBRNs) are promising for accelerating not only research, but also dissemination of research-based evidence into broader community practice. Sentinel lymph node biopsy (SLNB) is an innovation in breast cancer care associated with equivalent survival and lower morbidity, as compared to standard axillary lymph node dissection. We examined the diffusion of SLNB into practice and whether affiliation with the Community Clinical Oncology Program (CCOP), a cancer-focused PBRN, was associated with more rapid uptake of SLNB. Research Design Surveillance Epidemiology and End Results(SEER)-Medicare data were used to study women diagnosed with stage I or II breast cancer in the years 2000 to 2005 and undergoing breast conserving surgery with axillary staging (n=6,226). The primary outcome was undergoing SLNB. CCOP affiliation of the surgical physician was ascertained from NCI records. Multivariable generalized linear modeling with generalized estimating equations was used to measure association between CCOP exposure and undergoing SLNB, controlling for potential confounders. Results Women treated by a CCOP physician had significantly higher odds of receiving SLNB compared to women treated by a non-CCOP physician (OR 2.68; 95% CI 1.35, 5.34). The magnitude of this association was larger than that observed among patients treated by physicians operating in medical school-affiliated hospitals (OR 1.76; 95% CI 1.30–2.39). Conclusion Women treated by CCOP-affiliated physicians were more likely to undergo SLNB irrespective of the hospital’s medical school affiliation, suggesting that the CCOP PBRN may play a role in the rapid adoption of research-based innovation in community practice.

show abstract

Translating Research Into Practice

Cited by 27 publications

References 31 publications

Utilization of epidermal growth factor receptor (EGFR) testing in the United States: a case study of T3 translational research

Utilization of epidermal growth factor receptor (EGFR) testing in the United States: a case study of T3 translational research

Enrollment and Racial Disparities in Cancer Treatment Clinical Trials in North Carolina

Differential Receipt of Sentinel Lymph Node Biopsy Within Practice-based Research Networks

Contact Info

Product

Resources

About